Malignant Mesothelioma: Dual Checkpoint Immunotherapy as New Standard
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
CheckMate-743 Phase III Trial Approval
- July 17, 2021
- Reading time: 1 minute
On May 27, 2021, Ono Pharmaceutical and Bristol-Myers Squibb jointly announced regulatory approval of combined nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) immune checkpoint blockade for unresectable and recurrent malignant mesothelioma.
Regulatory Basis
Approval was based on interim analysis from CheckMate-743, an international Phase III randomized trial enrolling treatment-naive patients with unresectable malignant pleural mesothelioma.
Trial Design
Treatment Comparison:
- Nivolumab plus ipilimumab (dual checkpoint inhibition)
- Versus placebo plus platinum-based chemotherapy
Primary Endpoint: Overall survival
Key Clinical Outcomes
CheckMate-743 demonstrated that dual immune checkpoint blockade (nivolumab plus ipilimumab) achieves superior overall survival compared to standard platinum chemotherapy in unresectable malignant mesothelioma.
Safety Profile
- Adverse event profile consistent with established immunotherapy safety data
- No novel or unexpected toxicities identified
Clinical Significance
This approval represents a major advance in mesothelioma treatment, establishing dual checkpoint inhibition as a new standard first-line option for patients with unresectable disease, offering survival benefit over conventional chemotherapy.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1